Whats next? $HUGE
If elected at the Meeting, the Concerned Shareholders’ Nominees hope to restore FSD by: Focusing on acquiring biotechnology assets focused on legal medical cannabis and/or legal psychedelics to increase the Company’s drug development pipeline and reduce reliance on a single compound;auditing the Company’s current Phase 2 clinical trial to determine its current viability and better understand the risks and costs so that appropriate budgets can be created and followed and to determine whether it should be continued;implementing a strong financial and corporate governance framework so that directors and management are restricted in granting compensation to themselves at levels higher than industry standards;implementing audits of prior compensation and expenses incurred by the Company; and developing a robust investor relations function to better communicate FSD’s value to the investment community